Risk Factors ID'd for Poor Health-Related QOL in MS Patients
FRIDAY, Aug. 12, 2022 -- Early risk factors may predict health-related quality of life (HRQoL) for people with newly diagnosed multiple sclerosis (MS), according to a study published online Aug. 10 in Neurology. Julia O ' Mahony, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2022 Category: Pharmaceuticals Source Type: news

Who Fares Worse After Multiple Sclerosis Strikes?
THURSDAY, Aug. 11, 2022 -- For people with multiple sclerosis, certain factors early in their disease may determine their quality of life in the years to come, a new study suggests. In medicine, there are ways to objectively measure a disease ' s... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 11, 2022 Category: General Medicine Source Type: news

Does Epstein-Barr Cause MS? Predicting Chronic TBI Pain; Neural Flexibility in ADHD
(MedPage Today) -- A review in Nature Reviews Microbiology looks at evidence that suggests Epstein-Barr virus is a causal agent for multiple sclerosis (MS). Lifelong engagement in activities and reading ability were linked with better cognitive... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - August 9, 2022 Category: Neurology Source Type: news

Bed shortage blamed after Winnipeg patient with MS unwillingly moved to COVID ward
A Winnipeg hospital overwhelmed with more patients than it had capacity for sent a man who didn't have COVID-19, but lives with multiple sclerosis, into an outbreak ward where he says he shouldn't have been. (Source: CBC | Health)
Source: CBC | Health - August 3, 2022 Category: Consumer Health News Tags: News/Canada/Manitoba Source Type: news

Domestic violence experienced by women with multiple sclerosis: a study from the North-East of Iran - Manouchehri E, Ghavami V, Larki M, Saeidi M, Latifnejad Roudsari R.
INTRODUCTION: Violence against women is a significant health and legal problem and has been declared as a health priority by the World Health Organization. The most common type of violence against women is domestic violence, more prevalent against women wi... (Source: SafetyLit)
Source: SafetyLit - August 2, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Roche to present scientific progress across Alzheimer ’s disease pharmaceutical and diagnostic portfolio at 2022 AAIC Annual Meeting
Overview of two decades of research to be presented, including development ofgantenerumabDetailed results from phase II study evaluatingcrenezumab in autosomal dominant Alzheimer ' s diseaseData around biomarker selection for theElecsys Amyloid Plasma Panel, a blood-based biomarker test to aid in the detection of people with amyloid pathology, recently granted FDA Breakthrough Device DesignationBasel, 28 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data from 41 abstracts across its portfolio of Alzheimer ’s disease pharmaceuticals and diagnostics will be presented at the 2022 Alzheimer’s Associat...
Source: Roche Media News - July 28, 2022 Category: Pharmaceuticals Source Type: news

Multiple Sclerosis Highlights From EAN 2022 Multiple Sclerosis Highlights From EAN 2022
Key presentations in multiple sclerosis at EAN 2022 included updated EAN-ECTRIMS treatment guidelines, prognostic biomarker findings, and data on BTK inhibitors in RRMS, as reported by Prof Jens Kuhle.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 27, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery ReCAP Source Type: news

Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: a systematic review and meta-analysis - Peres DS, Rodrigues P, Viero FT, Frare JM, Kudsi SQ, Meira GM, Trevisan G.
Multiple sclerosis (MS) is a chronic neurodegenerative and autoimmune disease. Motor, sensory and cognitive deficits in MS are commonly accompanied by psychiatric disorders. Depression and anxiety affect the quality of life of MS patients, and the treatmen... (Source: SafetyLit)
Source: SafetyLit - July 25, 2022 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Off-Label Drug Lowers Relapses in Multiple Sclerosis
(MedPage Today) -- Off-label rituximab (Rituxan) led to fewer relapses over 2 years than dimethyl fumarate (Tecfidera) in people with early relapsing-remitting multiple sclerosis (MS), the phase III RIFUND-MS trial showed. Relapses occurred in... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 21, 2022 Category: Neurology Source Type: news

Multiple Sclerosis Patients on the Most Effective Ways Doctors Can Treat Their Condition
Because multiple sclerosis involves nerve damage that can occur throughout the body, including brain connections, symptoms can vary widely and be progressive. That makes each patient’s journey unique, and can prompt challenges on both sides of the exam table. Here’s what eight patients with the disease wish doctors knew when it comes to helping them manage the condition more effectively. Diagnosis should be its own appointment Although Dr. Claire Warren—a 70-year-old Stonington, N.Y.–based physician—has plenty of experience treating patients with all kinds of ailments, it wasn’t until sh...
Source: TIME: Health - July 21, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follic...
Source: Roche Media News - July 21, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andT...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news

AHN Specialists Studying New Treatment for Relapsing Multiple...
Doctors at Allegheny Health Network (AHN), led by neurologist Troy Desai, MD, are exploring the use of a new drug to treat relapsing or primary progressive multiple sclerosis (MS).(PRWeb July 21, 2022)Read the full story at https://www.prweb.com/releases/ahn_specialists_studying_new_treatment_for_relapsing_multiple_sclerosis/prweb18805043.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 21, 2022 Category: Pharmaceuticals Source Type: news

Facial Twitching and Multiple Sclerosis
Muscle spasms are common with multiple sclerosis. Here’s what to know if MS facial twitching affects you. (Source: WebMD Health)
Source: WebMD Health - July 18, 2022 Category: Consumer Health News Source Type: news

Cancer Med Might Be Powerful Treatment for MS
THURSDAY, July 14, 2022 -- A drug used " off-label " for multiple sclerosis (MS) is more effective than a standard medication at preventing symptom flare-ups, a new clinical trial has found. The drug, called rituximab, is approved in the United States... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 14, 2022 Category: General Medicine Source Type: news